Krsnaa Diagnostics Q1 FY27 Revenue up 22% to ₹2,355 million; Rajasthan ops live
Krsnaa Diagnostics reported Q1 FY27 revenue of ₹2,355 million, a 22% YoY increase. Rajasthan operations are now live, contributing ₹257 million. Retail revenue grew 64% YoY to ₹193 million. The Board approved a preferential warrant issue to promoters.
The revenue growth and operational expansion are positive indicators. The preferential warrant issue signals promoter confidence, which can be viewed positively by investors. However, the margin moderation in Rajasthan due to upfront costs and the fact that it's a quarterly result with future potential rather than a definitive outcome, places the impact at medium.
The company reported strong revenue growth, successful operationalization of new projects (Rajasthan), and promoter confidence through a warrant issue. Retail segment also showed significant growth.
Krsnaa Diagnostics Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a 22% year-on-year growth in revenue from operations, reaching ₹2,355 million (235.5 crore). Like-for-like projects saw a growth of approximately 12% YoY.
During the quarter, the Rajasthan pathology network became operational, contributing ₹257 million (25.7 crore) to the revenue. The company noted that the moderation in margins is due to the upfront fixed cost base in Rajasthan, which is expected to normalize as utilization increases.
Retail revenue demonstrated strong performance, growing approximately 64% YoY to ₹193 million (19.3 crore), with the retail network expanding to over 4,250 touchpoints across five states. The Board also approved the issue of share warrants to the Promoter and Promoter Group, subject to necessary approvals.
Other operational highlights include the inauguration of 8 out of 17 planned MRI centers in Maharashtra, the commencement of operations at Apulki-Pune hospital, and securing a new CT project award in Himachal Pradesh for 34 CT scanners. The company added 12 new NABH accreditations.
Managing Director, Mr. Yash Mutha, stated that the results reflect the growing strength of the platform, with existing business growth complemented by new projects. Group Chief Executive Officer, Mr. Mitesh Dave, emphasized the conversion of infrastructure into revenue-generating capacity and the expected visibility of operating leverage as utilization builds.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.